Improving delivery of cancer-fighting antibodies using a new polymer technology
Official title: The resurgence of antibody-drug conjugates via PMPC-polymer engineering
Funded at University of Alabama at Birmingham · NIH-10978870 · Data updated 2026-11-12
This study is exploring a new way to help deliver cancer-fighting antibodies more effectively in the body, especially for people with B-cell lymphomas, by using a special material that helps the antibodies stay in the bloodstream longer and reach the right places when needed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $585,228 |
| NIH project number | 1R01CA293907-01 |
| Project ID | NIH-10978870 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with B-cell lymphomas or other cancers that could benefit from enhanced antibody therapies.
✕Less likely to help
Patients with cancers that do not involve B-cells or those who are not candidates for antibody therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel polymer-based platform that enhances the delivery of therapeutic antibodies in the body. By using a super-hydrophilic polymer called PMPC, the platform aims to prolong the circulation of antibodies, ensure specific delivery to target areas, and protect them from the immune system. The approach also allows for targeted release of the antibodies in response to specific conditions, which could improve treatment outcomes for cancers like B-cell lymphomas. The research has shown promising results in animal models, including effective delivery to challenging areas like the central nervous system and lymph nodes.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with fewer side effects by improving how antibodies are delivered to tumors.
How similar studies have gone: Other research has shown success with similar antibody delivery technologies, indicating a promising avenue for clinical application.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Kamata, Masakazu — University of Alabama at Birmingham
- Study coordinator: Kamata, Masakazu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.